Cincinnati Children’s Partners with FDNA to Help Children with PACS1 Syndrome

September 26, 2017

Cincinnati Children’s Hospital & FDNA – “Today, Cincinnati Children’s Hospital Medical Center announced the results of its new collaboration with Boston-based FDNA to accelerate the identification of PACS1 Syndrome in affected patients.

PACS1 is an extremely rare genetic disease with roughly 30 confirmed cases globally. It results in mobility, motor and cognitive delays and disabilities. Through the collaboration and collection of syndrome data, Face2Gene can now recognize and detect associations between PACS1-related facial characteristics and other phenotypes and genes.

“According to recent studies, approximately one-third of all patients admitted to children’s hospitals have genetic disorders. Many of these are quite rare and traditionally can only be diagnosed when recognized by an astute clinician,” said Robert Hopkin, MD, in the Division of Human Genetics at Cincinnati Children’s. “PACS1 is typically confirmed using genetic testing, and now Face2Gene can help clinicians recognize the PACS1 phenotype earlier—especially where genetic testing is unavailable.”

Related articles

Pioneering Rare Disease Diagnosis in Italy with AI-Powered Innovations, in Dermatology and Genetics

Pioneering Rare Disease Diagnosis in Italy with AI-Powered Innovations, in Dermatology and Genetics

In a recent landmark scientific webinar trailblazing development in dermatological phenotyping, genetic disorders, and the transformative application of artificial intelligence (AI) in rare disease diagnostics in Italy were explored. The event convened leading experts, researchers, and clinicians, who unveiled their experience in the clinic, including the innovative use of an AI-powered called Face2Gene to significantly […]

Continue reading